Pharmaceutical firm Genentech (DNA: sentiment, chart, options) stepped into the earnings confessional after the closing bell today. The company reported second-quarter profit of $782 million, or 73 cents per share, compared to $747 million, or 70 cents per share, a year prior. Excluding items, DNA earned 82 cents per share. Analysts, on average, expected second-quarter earnings (excluding items) of 86 cents per share. Revenue for the period came in at $3.24 billion, up from $3 billion a year earlier and slightly higher than the Street's estimate of $3.23 billion.

Meanwhile, the company upped its full-year earnings guidance to a range of $3.40 to $3.50 per share, compared to previous predictions of a range of $3.35 to $3.45 per share.

At last check, the shares of DNA were trading near $76.14, up from their closing price of $75.39.

Ahead of the earnings results, the Street was relatively optimistic toward the equity. The stock's SOIR of 0.56 indicates that calls outnumber their put counterparts among options slated to expire within 3 months. This ratio ranks in the 26th annual percentile, meaning short-term option traders have been more bullishly aligned toward DNA only 26% of the time during the past year. What's more, Zacks reports that 13 out of 18 ranking analysts rate the stock a "buy" or better.

Copyright Schaeffer's Investment Research http://www.schaeffersresearch.com